The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Håkan Axelson

Håkan Axelson

Research team manager

Håkan Axelson

The Immunopeptidome from a Genomic Perspective : Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides


  • Georges Bedran
  • Hans Christof Gasser
  • Kenneth Weke
  • Tongjie Wang
  • Dominika Bedran
  • Alexander Laird
  • Christophe Battail
  • Fabio Massimo Zanzotto
  • Catia Pesquita
  • Hákan Axelson
  • Ajitha Rajan
  • David J. Harrison
  • Aleksander Palkowski
  • Maciej Pawlik
  • Maciej Parys
  • J. Robert O’Neill
  • Paul M. Brennan
  • Stefan N. Symeonides
  • David R. Goodlett
  • Kevin Litchfield
  • Robin Fahraeus
  • Ted R. Hupp
  • Sachin Kote
  • Javier A. Alfaro

Summary, in English

Tumor antigens can emerge through multiple mechanisms, including translation of noncoding genomic regions. This noncanonical category of tumor antigens has recently gained attention; however, our understanding of how they recur within and between cancer types is still in its infancy. Therefore, we developed a proteogenomic pipeline based on deep learning de novo mass spectrometry (MS) to enable the discovery of noncanonical MHC class I–associated peptides (ncMAP) from noncoding regions. Considering that the emergence of tumor antigens can also involve posttranslational modifications (PTM), we included an open search component in our pipeline. Leveraging the wealth of MS-based immunopeptidomics, we analyzed data from 26 MHC class I immunopeptidomic studies across 11 different cancer types. We validated the de novo identified ncMAPs, along with the most abundant PTMs, using spectral matching and controlled their FDR to 1%. The noncanonical presentation appeared to be 5 times enriched for the A03 HLA supertype, with a projected population coverage of 55%. The data reveal an atlas of 8,601 ncMAPs with varying levels of cancer selectivity and suggest 17 cancer-selective ncMAPs as attractive therapeutic targets according to a stringent cutoff. In summary, the combination of the open-source pipeline and the atlas of ncMAPs reported herein could facilitate the identification and screening of ncMAPs as targets for T-cell therapies or vaccine development.


  • Division of Translational Cancer Research
  • Kidney cancer research group
  • LUCC: Lund University Cancer Centre

Publishing year







Cancer immunology research





Document type

Journal article


American Association for Cancer Research


  • Biochemistry and Molecular Biology



Research group

  • Kidney cancer research group


  • ISSN: 2326-6066